MENLO PARK, Calif.--(BUSINESS WIRE)--Octave® Bioscience, a leading precision care company transforming the management of multiple sclerosis (MS) and other neurodegenerative diseases, today announced the appointment of Marcel Konrad as Chief Financial Officer. Marcel brings a distinguished track record in scaling high-growth therapeutic and diagnostic companies to Octave as the company enters a pivotal phase of commercial expansion.
The addition of Marcel follows several new appointments of proven commercial leaders, including CEO Doug Biehn, Chief Revenue Officer Jeron Evans, and Chief Access Officer Debbie Ledet.
“Marcel’s ability to build and scale high-performing financial organizations aligns perfectly with Octave’s ambitious growth trajectory,” said Doug Biehn, CEO of Octave. “His leadership will be invaluable as we expand our market reach, deepen customer relationships, and deliver exceptional value to patients and healthcare providers.”
Marcel has decades of experience as a growth-focused financial executive who has rapidly scaled innovative companies and built world-class teams. Prior to joining Octave, Marcel held several leadership positions in a range of companies in both therapeutics and clinical diagnostics such as Novartis, Santen, CareDx, and most recently Medexus Pharmaceuticals, a publicly traded innovative specialty pharmaceutical company for rare diseases.
"Octave is at an important inflection point as the company takes its commercial efforts to a new level of growth and scale, and I’m delighted to be part of its next chapter,” said Marcel Konrad. “I’m inspired by Octave’s mission to become the leader in precision care for neurodegenerative diseases, humbled to work with such a highly engaged and successful Board, and excited to be part of an experienced, collaborative team that will deliver on our mission.”
Brook Byers, Octave Board member, visionary life sciences investor and founding member of Kleiner Perkins Caufield & Byers commented, “Marcel is a credible leader who has built great teams, and has a proven ability to drive and scale large businesses. Octave is uniquely positioned to help people with MS and other neurodegenerative conditions with its highly differentiated Precision Care solution, and bringing on leaders like Marcel will help the company accelerate its growth and patient impact.”
This leadership expansion comes at an important growth phase for the company when Octave is demonstrating rapid provider adoption and repeat usage, expanding its scientific and clinical evidence, deepening strategic partnerships with Pharma companies to accelerate drug development and market differentiation, and providing health plans a value-based solution to improve health outcomes and reduce costs.
About Octave® Bioscience, Inc.
Octave® Bioscience, Inc. has developed the industry’s first comprehensive precision care solution for neurodegenerative diseases, starting with multiple sclerosis (MS). Octave’s Precision Care Solution addresses biological, imaging, and clinical insights to accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases. Octave’s Precision Care Solution is now in use in leading MS centers of excellence, including 10 of the top 20 MS COE in the US, academic centers, and high-volume independent clinics across the U.S. The company has also developed partnerships with leading pharmaceutical companies and health plans nationwide, and is also expanding into Parkinson’s with R&D work funded by The Michael J. Fox Foundation.
